Bosnalijek breaks its own business records

The largest domestic pharmaceutical company, Bosnalijek j.s.c., in the first nine months of 2022, achieved total revenue of 120.5 million BAM and thereby achieved revenue growth of 33.4 million BAM or 38 percent compared to the same period last year.


Bosnalijek breaks its own business records

The net income from sales was realized at 96.8 million BAM, which is 31 percent more compared to 74 million BAM of the realized income in the same period of 2021. Financial income in the amount of 23.2 million KM was also realized, which refers to positive exchange rate differences, income based on interest, and other financial income in the amount of 8,000 (eight thousand) BAM. Sales on foreign markets generated 61.2 million BAM or 63 percent of the total revenue from sales, while sales on the market of Bosnia and Herzegovina generated 35.5 million BAM or 37 percent of the total revenue from sales. Realized EBITDA, in the period of the first nine months of 2022, amounted to 36.8 million BAM and is 20.9 million BAM higher than the EBITDA realized in the first nine months of 2021. In the same period of 2022, profit before tax amounted to 24.8 million BAM, which is 22.3 million BAM higher than the realized profit before tax in the same period of the previous year.

The general director of Bosnalijek, Nedim Uzunović, emphasizes that the company's record business results were achieved despite major disruptions in the global market, thanks above all to the adequate adjustment of business processes and the enormous effort of all Bosnalijek employees.

"We are particularly pleased that, during the great world crisis and the numerous challenges we faced throughout the year, we managed not only to preserve our achieved positions but also to increase market share and revenues, both on foreign markets and on the market of Bosnia and Herzegovina. It certainly wasn't easy, but we proved for the umpteenth time that our strictly controlled and focused business strategy is correct and that we are capable of meeting all challenges.

Today, we are a global company that successfully operates in 28 markets on four continents, and we continue our successful development path in the coming period as well.”, said Uzunović.   



November 30, 2022
Previous news
Bosnalijek breaks its own business records Record semi-annual performance of Bosnalijek in 2022 Bosnalijek Opens New Facility for Manufacturing Liquid and Semisolid Pha ... Two Bosnalijek Teams Won Valuable Prizes at Dolorex B2B Night Relay Race ... Professional Lecture for Doctors and Patients Held On the Occasion of th ... Bosnalijek signs cooperation agreement with Mylan, a global healthcare c ... Bosnalijek Appoints US Major General David L. Grange (Ret.) as the Board ... The Third Congress of Pharmacists from Montenegro held in Bečići Foreign markets recognize the quality of our products Bosnalijek won the prestigious industry award
februar 09. 2023 |
SASE |
BSNLR - Bosnalijek d.d. Sarajevo: 12,47 3,89%